

A comprehensive study of HMG-CoA reductase in Uterine cancer with an *in silico* perspective


Priti Chatterjee*

*Assistant Professor, Department of Zoology, Krishnagar Govt. College, Krishnagar, Nadia, West Bengal, PIN- 741101, India.

e-mail: pritchatterz@gmail.com


INTRODUCTION & OBJECTIVE

Uterine Cancer and its types



Source: Website of Weill Cornell Medicine

Uterine Cancer and the global scenario



Background

Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy

Michel R. Hoening^{1,*}, Frank W. Selkoe²

Atherosclerosis
Journal homepage: www.elsevier.com/locate/atherosclerosis

cancers
Review
Insulin Resistance and Endometrial Cancer: Emerging Role for microRNA

Iwona Sidorowicz^{1,*}, Maciej Jędrlik², Magdalena Niemira¹ and Adam Kępcowski^{1,3}


¹ Clinical Research Centre, Medical University of Białystok, M. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland; magdalena.niemira@umb.edu.pl (A.K.); adam.kepcowski@umb.edu.pl (A.K.)
² Department of Gynecology and Gynecological Oncology, Medical University of Białystok, M. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland; jacovik@umb.edu.pl
³ Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, M. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland
* Correspondence: iwona.sidorowicz@umb.edu.pl; Tel.: +48-85-831-8893

Received: 30 July 2020; Accepted: 7 September 2020; Published: 8 September 2020

Treatment



Can fertility preservation be an option????



Objective

To understand the clinical implications of HMG-CoA reductase in both subtypes of uterine cancer.

METHODS

Methods (in silico)

DNA mutation

- Database- TCGA
- Webtool- CbioPortal

Expression At RNA level

- Database- TCGA, GTEx
- Webtools- UALCAN, Gepia2, OncoDB

Expression At Protein level

- Database- CPTAC
- Webtools- UALCAN

GEPIA2 <https://gepia2.cancer-pku.cn/>

OncoDB <https://oncodb.org/>

cbioPortal <https://www.cbioportal.org/>

UALCAN <https://ualcan.path.uab.edu/>

RESULTS AND DISCUSSION

Figure 1 Alteration Frequency






Figure 2: HMGCR is significantly upregulated in UCEC patients at mRNA level (GEPIA2). TCGA tumor samples in red (UCEC N= 174, UCS N= 57), TCGA + GTEx normal samples in grey (UCEC control =91; UCS control =78)

Figure 3a




Figure 3b





Figure 3

Gene	Probe	Chr	Position	Average of Cancer Sample	Average of Normal Sample	p-value
HMGCR	cg11803809	chr5	75336287	0.03	0.04	3.8e-04
HMGCR	cg07025548	chr5	75336652	0.04	0.05	1.5e-01
HMGCR	cg24854943	chr5	75337033	0.03	0.04	4.8e-02
HMGCR	cg05910138	chr5	75337097	0.02	0.03	2.1e-01
HMGCR	cg02162412	chr5	75337101	0.03	0.03	7.4e-02
HMGCR	cg18880544	chr5	75337110	0.03	0.03	8.2e-01
HMGCR	cg06434480	chr5	75337115	0.02	0.02	8.2e-01
HMGCR	cg10552847	chr5	75337141	0.02	0.02	6.8e-01
HMGCR	cg26685638	chr5	75337187	0.02	0.02	4.3e-01
HMGCR	cg09026481	chr5	75337197	0.01	0.02	2.7e-01
HMGCR	cg07732421	chr5	75337428	0.06	0.07	4.9e-02
HMGCR	cg00360362	chr5	75337702	0.05	0.05	3.4e-01
HMGCR	cg26399773	chr5	75337830	0.02	0.02	2.5e-01
HMGCR	cg11213898	chr5	75337995	0.02	0.02	8.8e-02
HMGCR	cg26510404	chr5	75361623	0.09	0.09	6.1e-01

Comparison	Statistical significance
Normal-vs-Primary	2.802600E-04

Figure 3: Promoter methylation of HMGCR is relatively lower in UCEC patients as derived from a) OncoDB and b) UALCAN (TCGA samples: Normal in blue, N=46; Primary Tumor in red, N= 438).


Expression of HMGCR in UCEC based on Menopause status



Comparison	Statistical significance
Normal-vs-Pre-Menopause	2.360099998763E-07
Normal-vs-Peri-Menopause	1.480070E-02
Normal-vs-Post-Menopause	1.62447832963153E-12
Pre-Menopause-vs-Peri-Menopause	4.946600E-01
Pre-Menopause-vs-Post-Menopause	3.612800E-01
Peri-Menopause-vs-Post-Menopause	6.511600E-01

Figure 4: HMGCR is significantly upregulated in UCEC patients in pre-menopause stage.

Figure 5



Comparison	Statistical significance
Normal-vs-Primary	6.30388516086518E-13

Figure 5: HMGCR is significantly upregulated in UCEC patients at protein level (UALCAN) CPTAC samples: Normal (blue) N= 31; Primary Tumor (red) N= 100

SUMMARY

- HMGCR shows higher percentage of mutational anomalies in UCEC patients compared to UCS patients.
- HMG CoA Reductase is increased at transcript levels in the UCEC samples but not in UCS tissues.
- The promoter region of HMG CoA Reductase gene has less methylation marks compared to normal samples indicating the transcriptional hyperactivity of the gene in UCEC.
- Therefore, statins might be an alternative choice of medication to harness endometrial cancer and is yet to be confirmed through *in vitro* studies.

FUTURE WORK-PLAN

- To identify the mutations of HMGCR and predict their impact on the protein structures and functions.
- To predict the high-concern mutations and their effect on the binding of statins through molecular docking. (comparing with Wildtype)
- This might help in predicting if the particular statin could be effective in pre-menopausal women.

ACKNOWLEDGEMENT

- Organizers of IECC 2026
- HOD, Department of Zoology, Krishnagar Govt. College.
- Faculty members, Department of Zoology, Krishnagar Govt. College.
- Dr. Achintya Mohan Goswami, Associate Professor, Department of Physiology, Krishnagar Govt. College.
- Dr. Debnath Palit, Principal, Krishnagar Govt. College.